Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Manni, Sabrina ^a,b   Brancalion, Alessandra ^a,b   Mandato, Elisa ^a,b   Tubi, Laura Quotti ^a,b   Colpo, Anna ^a,b   Pizzi, Marco ^a   Cappellesso, Rocco ^a   Zaffino, Fortunato ^a,b   Di Maggio, Speranza Antonia ^a   Cabrelle, Anna ^b   Marino, Filippo ^a   Zambello, Renato ^a,b   Trentin, Livio ^a,b   Adami, Fausto ^a   Gurrieri, Carmela ^a,b   Semenzato, Gianpietro ^a,b   Piazza, Francesco ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; BORTEZOMIB; CASEIN KINASE II; CASEIN KINASE II ALPHA; CASEIN KINASE II BETA; CELL CYCLE PROTEIN 37; CX 4945; CYCLIN D1; CYCLOOXYGENASE 2; ENDORIBONUCLEASE IRE1 ALPHA; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INHIBITOR OF APOPTOSIS PROTEIN 2; INITIATION FACTOR 2ALPHA; INTERLEUKIN 6; K 27; MESSENGER RNA; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE INHIBITOR; RIBONUCLEASE; STAT3 PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL STRESS; CELL SURVIVAL; CELLULAR PROTEOTOXIC STRESS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LYMPHOMA CELL LINE; MALE; MANTLE CELL LYMPHOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR MICROENVIRONMENT; UPREGULATION;

ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; BORONIC ACIDS; CASEIN KINASE II; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, MANTLE-CELL; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; NAPHTHYRIDINES; NF-KAPPA B; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84884682737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075280     Document Type: Article

References (55)

1. Kisselev AF, van der Linden WA, Overkleeft HS, (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19: 99-115.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC, (2009) Multiple myeloma. Lancet 374: 324-339.
3. Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M, (2012) Mantle cell lymphoma. Crit Rev Oncol Hematol 82: 78-101.
4. Mitsiades CS, Hideshima T, Chauhan D, McMillin DW, Klippel S, et al. (2009) Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 46: 166-175.
5. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, et al. (2013) From Bortezomib to Other Inhibitors of the Proteasome and Beyond. Curr Pharm Des 22: 4025-4038.
6. Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, et al. (2012) New proteasome inhibitors in myeloma. Current hematologic malignancy reports 7: 258-266.
7. Holkova B, Grant S, (2012) Proteasome inhibitors in mantle cell lymphoma. Best Pract Res Clin Haematol 25: 133-141.
8. Koprivnikar JL, Cheson BD, (2012) Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma. Future Oncol 8: 359-371.
9. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647.
10. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, et al. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114: 1046-1052.
11. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, et al. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101: 1530-1534.
12. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, et al. (2006) Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20: 1017-1027.
13. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, et al. (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67: 5418-5424.
14. Cenci S, Sitia R, (2007) Managing and exploiting stress in the antibody factory. FEBS letters 581: 3652-3657.
15. Todd DJ, Lee AH, Glimcher LH, (2008) The endoplasmic reticulum stress response in immunity and autoimmunity. Nature reviews Immunology 8: 663-674.
16. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, et al. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916.
17. Ruzzene M, Pinna LA, (2010) Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 1804: 499-504.
18. Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, et al. (2012) Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 26: 1174-1179.
19. Ruzzene M, Pinna LA (2009) Addiction to protein kinase CK2: A common denominator of diverse cancer cells? Biochim Biophys Acta.
20. Miyata Y, Nishida E, (2004) Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target. Ann N Y Acad Sci 1030: 150-157.
21. Miyata Y, (2009) Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell Mol Life Sci 66: 1840-1849.
22. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE, (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62: 6770-6778.
23. Kato T Jr, Delhase M, Hoffmann A, Karin M, (2003) CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell 12: 829-839.
24. Prowald A, Schuster N, Montenarh M, (1997) Regulation of the DNA binding of p53 by its interaction with protein kinase CK2. FEBS Lett 408: 99-104.
25. Bjorling-Poulsen M, Siehler S, Wiesmuller L, Meek D, Niefind K, et al. (2005) The 'regulatory' beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation. Oncogene 24: 6194-6200.
26. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, et al. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12: 668-677.
27. Hessenauer A, Schneider CC, Gotz C, Montenarh M, (2011) CK2 inhibition induces apoptosis via the ER stress response. Cell Signal 23: 145-151.
28. Hosoi T, Korematsu K, Horie N, Suezawa T, Okuma Y, et al. (2012) Inhibition of Casein Kinase 2 Modulates XBP1-GRP78 Arm of Unfolded Protein Responses in Cultured Glial Cells. PLoS One 7: e40144.
29. Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, et al. (2012) Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clin Cancer Res 18: 1888-1900.
30. Schneider CC, Ampofo E, Montenarh M, (2012) CK2 regulates ATF4 and CHOP transcription within the cellular stress response signalling pathway. Cell Signal 24: 1797-1802.
31. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, et al. (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108: 1698-1707.
32. Padgett CS, Lim JKC, Marschke RF, Northfelt DW, Andreopoulou E, et al. (2010) Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: interim report from the phase 1 clinical trial. Eur J Cancer 8: 131-132.
33. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, et al. (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70: 10288-10298.
34. Piazza F, Manni S, Tubi LQ, Montini B, Pavan L, et al. (2010) Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC cancer 10: 526.
35. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, et al. (2005) International staging system for multiple myeloma. J Clin Oncol 23: 3412-3420.
36. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, et al. (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111: 558-565.
37. Fassina A, Marino F, Siri M, Zambello R, Ventura L, et al. (2012) The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 92: 1574-1582.
38. Fassan M, Pizzi M, Battaglia G, Giacomelli L, Parente P, et al. (2010) Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J Clin Pathol 63: 692-696.
39. Ferguson AD, Sheth PR, Basso AD, Paliwal S, Gray K, et al. (2010) Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett.
40. Roue G, Perez-Galan P, Mozos A, Lopez-Guerra M, Xargay-Torrent S, et al. (2011) The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 117: 1270-1279.
41. Sarno S, Papinutto E, Franchin C, Bain J, Elliott M, et al. (2011) ATP site-directed inhibitors of protein kinase CK2: an update. Curr Top Med Chem 11: 1340-1351.
42. Bird TA, (1997) Schooley K, Dower SK, Hagen H, Virca GD (1997) Activation of nuclear transcription factor NF-kappaB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit. J Biol Chem 272: 32606-32612.
43. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr, (2000) Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 275: 32592-32597.
44. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
45. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, et al. (2003) Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol 199: 84-89.
46. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, et al. (2003) Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 44: 1477-1481.
47. Yared MA, Khoury JD, Medeiros LJ, Rassidakis GZ, Lai R, (2005) Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med 129: 990-996.
48. Zhang L, Yang J, Qian J, Li H, Romaguera JE, et al. (2012) Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120: 3783-3792.
49. Matsumoto G, Wada K, Okuno M, Kurosawa M, Nukina N, (2011) Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitylated proteins. Mol Cell 44: 279-289.
50. Mujtaba T, Dou QP, (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery medicine 12: 471-480.
51. Timofeeva OA, Plisov S, Evseev AA, Peng S, Jose-Kampfner M, et al. (2006) Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis. Oncogene 25: 7555-7564.
52. Harvey EJ, Li N, Ramji DP, (2007) Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-gamma-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis. Arter Thromb Vasc Biol 27: 806-812.
53. Wang H, Yang Y, Sharma N, Tarasova NI, Timofeeva OA, et al. (2010) STAT1 activation regulates proliferation and differentiation of renal progenitors. Cell Signal 22: 1717-1726.
54. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, et al. (2011) A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 118: 156-166.
55. Schewe DM, Aguirre-Ghiso JA, (2009) Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 69: 1545-1552.